The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
Authors:
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 5 (6) , 801-812
Abstract
No abstract availableKeywords
Funding Information
- Otsuka Pharmaceutical Development & Commercialization
This publication has 14 references indexed in Scilit:
- A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKDKidney International Reports, 2020
- Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life InstrumentAmerican Journal of Kidney Diseases, 2018
- Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 TrialThe Journal of Clinical Pharmacology, 2017
- Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials DatabaseDrug Safety, 2015
- Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2014
- Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2013
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney diseaseKidney International, 2011
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009
- Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1The Lancet, 1994